123 related articles for article (PubMed ID: 32472163)
21. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia.
Lalloyer F; Fiévet C; Lestavel S; Torpier G; van der Veen J; Touche V; Bultel S; Yous S; Kuipers F; Paumelle R; Fruchart JC; Staels B; Tailleux A
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2731-7. PubMed ID: 17008586
[TBL] [Abstract][Full Text] [Related]
22. Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.
Dheer Y; Chitranshi N; Gupta V; Abbasi M; Mirzaei M; You Y; Chung R; Graham SL; Gupta V
Mol Neurobiol; 2018 Dec; 55(12):9043-9056. PubMed ID: 29637440
[TBL] [Abstract][Full Text] [Related]
23. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
[TBL] [Abstract][Full Text] [Related]
24. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.
Nahoum V; Pérez E; Germain P; Rodríguez-Barrios F; Manzo F; Kammerer S; Lemaire G; Hirsch O; Royer CA; Gronemeyer H; de Lera AR; Bourguet W
Proc Natl Acad Sci U S A; 2007 Oct; 104(44):17323-8. PubMed ID: 17947383
[TBL] [Abstract][Full Text] [Related]
25. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo.
Mukherjee R; Strasser J; Jow L; Hoener P; Paterniti JR; Heyman RA
Arterioscler Thromb Vasc Biol; 1998 Feb; 18(2):272-6. PubMed ID: 9484993
[TBL] [Abstract][Full Text] [Related]
26. The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation
Gaunt CM; Rainbow DB; Mackenzie RJ; Jarvis LB; Mousa HS; Cunniffe N; Georgieva Z; Brown JW; Coles AJ; Jones JL
Front Immunol; 2021; 12():712241. PubMed ID: 34447379
[TBL] [Abstract][Full Text] [Related]
27. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
[TBL] [Abstract][Full Text] [Related]
28. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes.
Howell SR; Shirley MA; Ulm EH
Drug Metab Dispos; 1998 Mar; 26(3):234-9. PubMed ID: 9492386
[TBL] [Abstract][Full Text] [Related]
29. Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.
Tachibana M; Shinohara M; Yamazaki Y; Liu CC; Rogers J; Bu G; Kanekiyo T
Exp Neurol; 2016 Mar; 277():1-9. PubMed ID: 26688581
[TBL] [Abstract][Full Text] [Related]
30. Activation of RXR by bexarotene inhibits inflammatory conditions in human rheumatoid arthritis fibroblast‑like synoviocytes.
Li Y; Xing Q; Wei Y; Zhao L; Zhang P; Han X; Wang J
Int J Mol Med; 2019 Nov; 44(5):1963-1970. PubMed ID: 31545398
[TBL] [Abstract][Full Text] [Related]
31. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
Wagner CE; Jurutka PW
Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
[TBL] [Abstract][Full Text] [Related]
32. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat.
Murillo-Rodríguez E; Vázquez E; Millán-Aldaco D; Palomero-Rivero M; Drucker-Colin R
Eur J Pharmacol; 2007 May; 562(1-2):82-91. PubMed ID: 17336288
[TBL] [Abstract][Full Text] [Related]
33. Coadministration of VDR and RXR agonists synergistically alleviates atherosclerosis through inhibition of oxidative stress: An in vivo and in vitro study.
Lin LM; Peng F; Liu YP; Chai DJ; Ning RB; Xu CS; Lin JX
Atherosclerosis; 2016 Aug; 251():273-281. PubMed ID: 27428295
[TBL] [Abstract][Full Text] [Related]
34. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
Monti JM; Jantos H
Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
[TBL] [Abstract][Full Text] [Related]
35. Preclinical PET Neuroimaging of [11C]Bexarotene.
Rotstein BH; Placzek MS; Krishnan HS; Pekošak A; Collier TL; Wang C; Liang SH; Burstein ES; Hooker JM; Vasdev N
Mol Imaging; 2016; 15():. PubMed ID: 27553293
[TBL] [Abstract][Full Text] [Related]
36. Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer.
Leal AS; Hung PY; Chowdhury AS; Liby KT
Pharmacol Ther; 2023 Dec; 252():108561. PubMed ID: 37952906
[TBL] [Abstract][Full Text] [Related]
37. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
[TBL] [Abstract][Full Text] [Related]
38. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
Heck MC; Wagner CE; Shahani PH; MacNeill M; Grozic A; Darwaiz T; Shimabuku M; Deans DG; Robinson NM; Salama SH; Ziller JW; Ma N; van der Vaart A; Marshall PA; Jurutka PW
J Med Chem; 2016 Oct; 59(19):8924-8940. PubMed ID: 27592633
[TBL] [Abstract][Full Text] [Related]
39. A partial agonist for retinoid X receptor mitigates experimental colitis.
Onuki M; Watanabe M; Ishihara N; Suzuki K; Takizawa K; Hirota M; Yamada T; Egawa A; Shibahara O; Nishii M; Fujihara M; Makishima M; Takahashi D; Furusawa Y; Kakuta H; Hase K
Int Immunol; 2019 Mar; 31(4):251-262. PubMed ID: 30590577
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Mukherjee R; Davies PJ; Crombie DL; Bischoff ED; Cesario RM; Jow L; Hamann LG; Boehm MF; Mondon CE; Nadzan AM; Paterniti JR; Heyman RA
Nature; 1997 Mar; 386(6623):407-10. PubMed ID: 9121558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
